Gene Therapy Market Top Companies Study -Krystal Biotech, Inc., Shanghai Sunway Biotech Co. Ltd., Sibiono Genetech Co. Ltd., Ferring B.V., Vertex Pharmaceuticals Incorporated.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy Market- (By Type (Gene silencing, Cell replacement, Gene augmentation, Other therapies), By Vector (Viral vectors (Retroviral Vectors (Gamma Retroviral Vectors, Lentiviral Vectors), Adeno-Associated Viral Vectors, Other Viral Vectors), Non-Viral Vectors (Oligonucleotides, Other Non-Viral Vectors)), By Therapeutic area (Neurology, Oncology, Hepatology, Other therapeutic areas), By Delivery method (In Vivo, Ex Vivo), By Route Of Administration (Intravenous, Other routes of administration))), Trends, Industry Competition Analysis, Revenue and Forecast To 2034"

According to the latest research by InsightAce Analytic, the Global Gene Therapy Market is valued at USD 2.4 Bn in 2024, and it is expected to reach USD 13.6 Bn by the year 2034, with a CAGR of 19.05% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2215

Gene therapy represents an advanced medical strategy that entails the modification or replacement of genetic material within a patient's cells to treat or prevent diseases. Its primary objective is to correct or alter gene functions that are either defective or contribute to the onset of disease. The global gene therapy market is witnessing robust growth, driven by ongoing advancements in biotechnology that are enabling the development of innovative therapies for a range of genetic disorders.

Key factors propelling market expansion include increased research and development efforts, supportive regulatory environments, and heightened collaboration among pharmaceutical and biotechnology companies. North America and Europe currently dominate the market, benefiting from well-established healthcare infrastructures, active clinical research programs, and substantial investment in gene-editing technologies. As more gene therapy candidates progress through clinical trials and receive regulatory approvals, the market is poised for continued growth. This progression is expected to unlock new therapeutic options for individuals with genetic conditions and contribute meaningfully to the advancement of the global healthcare sector.

List of Prominent Players in the gene therapy market:
• Novartis Ag
• Biogen Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Alnylam Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Amgen, Inc.
• Orchard Therapeutics Plc
• F. Hoffmann-La Roche Ag
• Jazz Pharmaceuticals Plc
• Uniqure N.V.
• Johnson & Johnson
• Bluebird Bio, Inc.
• Biomarin Pharmaceutical Inc.
• Krystal Biotech, Inc.
• Shanghai Sunway Biotech Co. Ltd.
• Sibiono Genetech Co. Ltd.
• Ferring B.V.
• Vertex Pharmaceuticals Incorporated
• Pfizer, Inc.
• Sangamo Therapeutics, Inc.
• Regenxbio
• Ultragenyx Pharmaceutical Inc.
• Meiragtx Holdings Plc
• Anges, Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
Gene therapy products undergo rigorous regulatory evaluation prior to approval, and their ability to address the underlying genetic causes of disease offers therapeutic outcomes that are often more durable and effective than conventional treatments. This distinct clinical advantage has contributed to a notable increase in regulatory approvals, with the U.S. Food and Drug Administration (FDA) authorizing over ten gene therapy products between 2021 and 2023. Additionally, a significant number of gene therapy candidates currently in the clinical development pipeline are expected to receive approval in the coming years. These developments are key drivers supporting the sustained growth of the global gene therapy market.

Challenges:
Despite its promising potential, the gene therapy market faces a range of challenges that may hinder its broader adoption. Chief among these is the high cost of treatment, which restricts accessibility for many patients. Concerns regarding long-term safety, the need for post-treatment monitoring, and the potential for adverse effects continue to necessitate cautious oversight. Regulatory complexities, limited reimbursement frameworks, and difficulties in achieving scalable and consistent manufacturing processes also present substantial barriers to market growth. Furthermore, ethical considerations and societal perceptions surrounding genetic modification remain a point of contention. Addressing these challenges will be crucial to ensuring the continued expansion and societal acceptance of gene therapy.

Regional Trends:
North America is a dominant region in the gene therapy market, supported by cutting-edge advancements in biotechnology and a favorable regulatory landscape. The presence of major industry players, combined with substantial investments in research and development, has reinforced the region's leadership position. The United States, in particular, plays a pivotal role, hosting a large number of clinical trials and achieving several notable product approvals. Collaborative initiatives between pharmaceutical companies and academic institutions are further accelerating innovation in the field. North America is expected to maintain its leading position in the gene therapy market, with continued focus on expanding therapeutic options for genetic disorders.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2215

Recent Developments:
• In May 2023, Novartis acquired a candidate gene therapy from Avrobio, a company experiencing financial challenges. Novartis made an unprecedented advance payment of $87.5 million for the clinical-phase asset, with no stipulations regarding future payments. The agreement encompassed AVR-RD-04, a hematopoietic stem cell gene therapy program under investigation designed to treat the uncommon genetic disorder cystinosis.
• In April 2023, Bristol-Myers Squibb expanded its global cell therapy manufacturing network. This expansion will enable in-house viral vector production via a manufacturing facility in the United States and its activities in Libertyville, Illinois. To make this happen, the business has signed an arrangement with Novartis. The facility and its operations could generate viral vectors for both of Bristol Myers Squibb's CAR T cell treatments. This advancement furthered the company's long-term goals in cell therapy.

Segmentation of Gene therapy market-
By Type
• Gene silencing
• Cell replacement
• Gene augmentation
• Other therapies
By Vector
• Viral vectors
o Retroviral Vectors
 Gamma Retroviral Vectors
 Lentiviral Vectors
o Adeno-Associated Viral Vectors
o Other Viral Vectors
• Non-Viral Vectors
o Oligonucleotides
o Other Non-Viral Vectors
By Therapeutic area
• Neurology
• Oncology
• Hepatology
• Other therapeutic areas
By Delivery method
• In Vivo
• Ex Vivo
By Route Of Administration
• Intravenous
• Other routes of administration
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/gene-therapy-market/2215

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.